SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease

Published: 20 July 2021

  • Views:

    Views Icon 25024
  • Likes:

    Heart Icon 7
  • episode_image
    14m 38s
    Part 1 | Session 6 Panel Discussion Stefan Anker, Shelley Zieroth, Andrew JS Coats, Bernard Zinman, John JV McMurray, Katherine Tuttle
  • episode_image
    6m 58s
    Part 2 | Session 4 Panel Discussion Andrew JS Coats, Gerasimos Filippatos, Shelley Zieroth, Stefan Anker
Average (ratings)
No ratings
Your rating

Overview

Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders. 

 

The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.

 

In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities.  Audience questions were submitted throughout and were addressed by the panel experts.

Educational Objectives

SGLT2 Inhibition in Cardiorenal Disease

  • Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
  • Apply findings from clinical trials into clinical practice
  • Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
  • Evaluate the safety and cardiorenal benefits of glucose-lowering agents
  • Implement the new guidelines of the HFA of the ESC in clinical practice

Target Audience

  • Cardiologists
  • Nephrologists
  • Endocrinologists

More from this programme

Part 2

SGLT2 Inhibitors in Heart Failure: A Practical Approach

Part 3

Meet The Expert: Implications for Clinical Practice - Breakout 1

Totality of Evidence for the Cardiorenal Patient - discussion with Alice Cheung and Andrew Coats. Session supported by an unrestricted grant from AstraZeneca

Part 4

Meet The Expert: Implications for Clinical Practice - Breakout 2

SGLT2i and QoL Improvement - discussion with Shelley Zieroth and John Spertus.

Part 5

Meet The Expert: Implications for Clinical Practice - Breakout 3

Age groups and vulnerable patients with Gerasimos Filippatos and Giuseppe Rosano.

Part 7

SGLT2 Inhibitors for Heart Failure: The New Standard of Care

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance

Part 8

Meet The Expert: Implications for Clinical Practice - Breakout 4

Early Treatment Initiation in the Hospital Setting - discussion with Marc Petrie and Deepak Bhatt. Session supported by an unrestricted grant from AstraZeneca

Part 9

Meet The Expert: Implications for Clinical Practice - Breakout 5

Managing Patients with Comorbidities (T2D & CKD) - discussion with Paola Fioretto and Katherine Tuttle. Session supported by an unrestricted grant from AstraZeneca

Part 10

Meet The Expert: Implications for Clinical Practice - Breakout 6

Interdisciplinary Collaboration and Care Transitions - discussion with Subodh Verma. Session supported by an unrestricted grant from AstraZeneca

Faculty Biographies

Alice Cheng

Alice Cheng

Endocrinologist

Dr Alice Cheng is an Associate Professor at University of Toronto, Toronto, CA and Endocrinologist at Trillium Health Partners.

Dr Cheng has been involved with the development of the Diabetes Canada clinical practice guidelines since 2003 and served as Chair for the 2013 version.

 

View full profile
Andrew JS Coats

Andrew JS Coats

Professor of Cardiology and Scientific Director

Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.

Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.

He is an…

View full profile